For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Anyone who has diabetes, high blood pressure, heart problems or has a family history of the disease is at increased risk for ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Deficiency of the pancreatic progenitor cell differentiation and proliferation factor gene was identified as a risk factor ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Some drugs are known as nephrotoxic, which means that their effects can cause damage to the kidneys. Drugs such as certain ...

Jen Muston, the head coach of the York College of Pennsylvania women's lacrosse team, has led the Spartans to 10 conference ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...